ERYtech Pharma Presents Very Encouraging Results of Its R&D Platform at the AACR in Denver

LYON, France & PHILADELPHIA--(BUSINESS WIRE)--Apr 17, 2009 - ERYtech Pharma will present very encouraging results of its R&D platform at the annual meeting of the American Association of Cancer Research at the Colorado Convention Center in Denver (CO) between 18th to 21th April.

Three subjects will be exposed on posters:

  • In situ dendritic cells-based cancer immunotherapy: antigen carried by erythrocytes targets Dentritic Cells
  • Allosteric hemoglobin effector loaded erythrocytes improve the efficacy of radiotherapy
  • Efficacy of L-asparaginase loaded red blood cells in combination with gemcitabine in mice bearing PANC-1 ( pancreatic carcinoma)

These different applications show the innovative capacities of the ERYtech Pharma technology.

Sunday, April 19, 2009

In situ dendritic cells-based cancer immunotherapy: antigen carried by erythrocytes targets DC

8:00 am - 12:00 pm - Poster Session Cancer Vaccines: Preclinical and Animal Models

Immunology 1 Hall B-F, Poster Section 16, Poster Board Number 6, #351

Monday, April 20, 2009

Allosteric hemoglobin effector loaded erythrocytes improve the efficacy of radiotherapy

1:00 pm - 5:00 pm - Poster Session Radiosensitizers and Radioprotectors

Tumor Biology 24 Hall B-F, Poster Section 9, Poster Board Number 10, #2299

Tuesday, April 21, 2009

Efficacy of L-asparaginase loaded red blood cells in combination with gemcitabine in mice bearing PANC-1

1:00 pm - 5:00 pm - Poster Session Combination Chemotherapy 2

Experimental and Molecular Therapeutics 31 Hall B-F, Poster Section 33 Poster Board Number 27, #4594

About ERYtech Pharma http://www.erytech.com

ERYtech Pharma is a specialty pharma company developing a new generation of drugs. GRASPA®, its most advanced product, has achieved its Phase II clinical trial in Acute Lymphoblastic Leukemia.

A pioneer in the encapsulation of therapeutic molecules into red blood cells, ERYtech Pharma is developing a pipeline of innovative therapeutic solutions based on its proprietary technology and expertise in the physiological properties of erythrocytes. The company addresses serious pathologies, orphan indications or sub-populations of patients, particularly in the fields of haematology, cancer and metabolic diseases.

Website

www.erytech.com

Contact: ERYtech Pharma
Press contact: Cathy CLEMENT – GAIA Communication
Tel : (0)1 30 82 66 65 – cathy.clement@gaiacommunication.fr
or
Other contacts:
Tel : +33 (0) 4 78 74 44 38 - Fax : +33 (0) 4 78 75 56 29
contact@erytech.com
or
Phone: 1 (215) 966 6190 - Fax: 1 (215) 966 6101

Posted: April 2009

View comments

Hide
(web5)